CA2287538A1 - Truncated vegf-related proteins - Google Patents

Truncated vegf-related proteins Download PDF

Info

Publication number
CA2287538A1
CA2287538A1 CA002287538A CA2287538A CA2287538A1 CA 2287538 A1 CA2287538 A1 CA 2287538A1 CA 002287538 A CA002287538 A CA 002287538A CA 2287538 A CA2287538 A CA 2287538A CA 2287538 A1 CA2287538 A1 CA 2287538A1
Authority
CA
Canada
Prior art keywords
vrp
truncated
subunit
sequence
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002287538A
Other languages
English (en)
French (fr)
Inventor
Peter Bohlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Collateral Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2287538A1 publication Critical patent/CA2287538A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002287538A 1997-04-25 1998-04-20 Truncated vegf-related proteins Abandoned CA2287538A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84298497A 1997-04-25 1997-04-25
US08/842,984 1997-04-25
PCT/US1998/007801 WO1998049300A2 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins

Publications (1)

Publication Number Publication Date
CA2287538A1 true CA2287538A1 (en) 1998-11-05

Family

ID=25288752

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002287538A Abandoned CA2287538A1 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins

Country Status (10)

Country Link
EP (1) EP0977854A2 (de)
JP (1) JP2001524828A (de)
KR (1) KR20010020259A (de)
CN (2) CN1680442A (de)
AU (1) AU7250298A (de)
CA (1) CA2287538A1 (de)
EA (1) EA199900861A1 (de)
IL (1) IL132537A0 (de)
NZ (2) NZ514872A (de)
WO (1) WO1998049300A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP0751992B1 (de) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
CA2231400A1 (en) 1995-09-08 1997-03-13 Genentech, Inc. Vegf-related protein
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
JP2002505873A (ja) * 1998-03-13 2002-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 血管内皮増殖因子２
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
EP1121143A2 (de) * 1998-03-27 2001-08-08 Dorothea J. Eicher Vegf und vegf-c als säuglingsnahrungsmittelzusätze
WO2000014105A1 (en) 1998-09-08 2000-03-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
EP1568375A1 (de) * 1998-10-26 2005-08-31 Ludwig Institute For Cancer Research Verwendung von VEGF-C oder VEGF-D Genen oder Proteinen zur Vorbeugung der Restenose
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
CN1338943A (zh) * 1998-10-26 2002-03-06 路德维格癌症研究院 利用vegf－c或vegf－d基因或蛋白预防再狭窄
ATE406907T1 (de) 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
WO2001077328A1 (en) * 2000-04-06 2001-10-18 Franco Wayne P Methods of using growth factors for treating heart disease
EP1157999A1 (de) * 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
AU8473401A (en) 2000-08-04 2002-02-18 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
AU2001277733A1 (en) * 2000-08-10 2002-02-25 Center For Advanced Science And Technology Incubation, Ltd. Chimeric human-type vascular endothelial cell growth factor
EP1191104A1 (de) * 2000-09-26 2002-03-27 Introgene B.V. Genträger und deren Verwendung zur Herstellung von Arzneimitteln und/oder Impfstöffen
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
CA2431308C (en) 2000-12-07 2010-04-13 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
KR20030093316A (ko) 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 혈관 내피 성장 인자 ２
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
EP1581241A4 (de) * 2001-06-20 2005-11-09 Ludwig Inst Cancer Res Stimulation von vaskularisierung mit vegf-b
UA75980C2 (en) 2001-10-15 2006-06-15 Janssen Pharmaceutica Nv Substituted 4-pheny1-4-[1h-imidazol-2-yl] piperidine derivative for reducing ischaemic damages
WO2006055743A2 (en) * 2004-11-18 2006-05-26 Franco, Wayne Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs
WO2010078624A1 (en) * 2009-01-07 2010-07-15 Vegenics Limited Materials and methods for the treatment of hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1242149B (it) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
WO1994011506A1 (en) * 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
CN1136920C (zh) * 1995-02-28 2004-02-04 加利福尼亚大学董事会 基因转移介导的血管形成疗法
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
HU223438B1 (hu) * 1995-03-02 2004-07-28 Amrad Operations Pty. Ltd. Új növekedési faktor és ezt kódoló génszekvencia
EP0873348A4 (de) * 1995-06-06 2000-11-08 Human Genome Sciences Inc Menschlicher vaskularer endothelialer wachtumsfaktor 3

Also Published As

Publication number Publication date
NZ500530A (en) 2001-12-21
KR20010020259A (ko) 2001-03-15
WO1998049300A2 (en) 1998-11-05
EA199900861A1 (ru) 2000-06-26
JP2001524828A (ja) 2001-12-04
AU7250298A (en) 1998-11-24
NZ514872A (en) 2005-01-28
EP0977854A2 (de) 2000-02-09
CN1680442A (zh) 2005-10-12
IL132537A0 (en) 2001-03-19
CN1260835A (zh) 2000-07-19
WO1998049300A3 (en) 1999-03-11

Similar Documents

Publication Publication Date Title
CA2287538A1 (en) Truncated vegf-related proteins
EP0925360B1 (de) Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten
US6479654B1 (en) Forms of the angiogenic factor vascular endothelial cell growth factor: VEGF
JP2000069982A (ja) ヒト血管内皮増殖因子２
CA2220912A1 (en) Human ccn-like growth factor
CA2322748A1 (en) Vascular endothelial growth factor 2
JP2002541829A (ja) 遺伝子治療および治療的スクリーニングに有用なｅＮＯＳ変異体
US20030165467A1 (en) Angiogenic factor and use thereof in treating cardiovascular disease
EP1141293A2 (de) Vaskulärer endothelialwachstumsfaktor x
EP0796325A1 (de) Menschlicher, vaskulärer ibp-änhlicher wachstumsfaktor
US20020034738A1 (en) Human vascular ibp-like growth factor
US6287812B1 (en) Nucleic acid molecules encoding cytostatin I
EP1426444A2 (de) Verwendung des angiogenischen Faktors VEGF145 in der Behandlung kardiovaskulärer Krankheiten
US20060084622A1 (en) Angiogenic factor and use thereof in treating cardiovascular disease
Neufeld et al. VEGF 145 expression vectors
AU8936101A (en) Angiogenic factor and use thereof in treating cardiovascular disease
KR100407087B1 (ko) 사람혈관성ibp-유사성장인자
AU2004200697A1 (en) Variants of the Angiogenic Factor Vascular Endothelial Cell Growth Factor: VEGF
CA2206640A1 (en) Human vascular ibp-like growth factor
JP2002247983A (ja) ヒト血管ｉｂｐ様成長因子

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued